All Clinical Trials

Clinical Trial NCT04064827

A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years with Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis

  • ClinicalTrials.gov ID: NCT04064827
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: RAYMOND PHILLIP QUIGLEY

objective

To evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution for the treatment of secondary hyperparathyroidism (SHPT) in pediatric subjects 0 to 9 years of age with stage 5 chronic kidney disease (CKD), receiving peritoneal dialysis (PD) or hemodialysis (HD).

If you are interested in this clinical trial, please contact Melaku Lemma on the Children’s Health Research Team.Call 214-456-8577Email